Tango Therapeutics, Inc.
For the period ended Oct 23, 2026. Filed Oct 23, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 23, 2026 · Filed Oct 23, 2026
Use the contents to explore the available documents and sections.
TNGX$21.50+3.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Data highlights include:
Data highlights include:
Clinical activity, all dose levels:
| • | 54% ORR (19/35; 18 cPRs,1 confirmed complete response) |
| • | 61% 9-month PFS |
| • | 97% DCR |
Safety and tolerability, all dose levels:
Vopimetostat plus zoldonrasib was generally well-tolerated across dose levels:
| • | There were no DLTs |
| • | There were no withdrawals due to TRAEs |
| • | The rate of dose reduction was 15% (6/39) |
| • | There were no Grade 5 TRAEs and there was one Grade 4 TRAE (3%) |
| • | The rate of Grade 3 TRAEs was 28% (11/39) |
| • | The most common TRAEs were nausea (39%), vomiting (39%), dysgeusia (28%) and fatigue (26%); all these events were Grade 1-2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.